Merck Expands Bravecto Label for Dogs

Merck Animal Health has received FDA approval to broaden the label for its popular flea and tick medication, Bravecto, for use in dogs. The expanded approval now covers a wider range of tick species, enhancing the product's utility for veterinarians and pet owners. This regulatory milestone allows Bravecto to offer more comprehensive protection against tick-borne diseases. The update signifies Merck's commitment to advancing animal health solutions and providing effective parasite control for canine companions.